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Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria has been
changed from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (AL) in 2006. The objective of this
study was to assess the effectiveness of AL in Jimma Zone two to three years after its broad introduction.
Methods: An open-label, single-arm, 42-day study of AL against falciparum malaria was conducted in four areas
with moderate transmission in Jimma Zone between November 2008 and January 2009 and between August and
December 2009. Patients (one-81 years) with uncomplicated Plasmodium falciparum mono-infection were
consecutively enrolled. Follow-up visits were at day 2, 3, 7, 28 and 42 or any other day if symptoms reoccurred.
Primary and secondary endpoints were PCR-corrected and uncorrected cure rates (molecular differentiation
between recrudescence and re-infection) on days 28 and 42. Other secondary endpoints were gametocytaemia at
day 7 and day 28, parasitaemia at day 2 and 3, and re-infection rates at day 28 and day 42.
Results: Of 348 enrolled patients, 313 and 301 completed follow-up at day 28 and at day 42, respectively. No early
treatment failure occurred. For per protocol analysis, PCR-uncorrected cure rates at day 28 and 42 were 99.1% (95%
CI 98.0-100.0) and 91.1% (95% CI 87.9-94.3), respectively. PCR-corrected cure rates at day 28 and 42 were 99.4%
(95% CI 98.5-100.0) and 94.7% (95% CI 92.2-97.2), respectively. PCR-corrected cure rate at day 42 for children
≤5 years was 90.6% (95% CI 82.4-98.7) only. Adverse events were in general mild to moderate. Incidence of new
infections was 3.4% during 42 days, no new infections with Plasmodium vivax were observed. Microscopically
detected gametocytaemia was reduced by 80% between day 0 and day 7.
Conclusion: In general, AL was effective and well tolerated in Jimma Zone, Ethiopia. However, the PCR-corrected
recrudescence rate per-protocol at day 42 for children ≤5 years was 9.4%. Therefore, further development should
be monitored on a regular basis as recommended by WHO.
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Due to increasing resistance of Plasmodium falciparum
against previous anti-malarials, such as chloroquine and
sulphadoxine-pyrimethamine (SP), most African coun-
tries, including Ethiopia, have changed their national
policy in recent years towards first-line treatment with
artemisinin-based combination therapy (ACT) [1,2].
ACT produces faster relief of clinical symptoms and
parasite clearance in uncomplicated P. falciparum mal-
aria than any other currently available anti-malarial drug
[3,4]. It combines the potential of rapid reduction of the
parasite burden with the elimination of remaining para-
sites due to longer acting partner drugs [5]. ACT seems
to be well tolerated as several studies indicate; no severe
side effects have been observed, especially for the com-
bination artemether-lumefantrine (AL) [6,7].
Malaria is endemic in approximately 75% of the na-
tional territory of Ethiopia. About 50 million inhabitants
are at risk of infection. In 2009, there was a considerable
increase of malaria-associated morbidity and mortality
in the south and south-west of Ethiopia, including the
town of Jimma and its surroundings, with most cases
occurring from September to December. Predominant
species was P. falciparum, but a trend to mixed and
mono-infections with Plasmodium vivax was observed
[8,9], pers comm with local health centres]. AL was
introduced in Ethiopia as first-line treatment for uncom-
plicated falciparum malaria in 2004 and became avail-
able in Jimma Zone in 2006. Since then, AL was
provided free of charge at public health centres by the
government only.
Increasing recrudescence rates and reduced in vitro re-
sponse to artemisinins were first reported from some
Asian countries [10], where artesunate monotherapy has
commonly been used for some decades. Along with
sub-therapeutic doses, incomplete treatment courses,
substandard and fake artemisinin-based drugs, this con-
stitutes a major risk factor for the development of drug
resistance. In 2008, the alarming news of delayed para-
site clearance rates after treatment with artesunate
monotherapy in Cambodia arrived. Reports on increas-
ing recrudescence and late clearance rates with ACT
followed [11-14]. A new definition for artemisinin resist-
ance was introduced by the WHO [10]. Interestingly,
slow clearance rates did not seem to be associated with
decreased sensitivity to drugs in vitro, but were asso-
ciated with parasite genetics in Cambodia [15]. Resist-
ance spread on a genetic basis would enormously
compromise the recent success of ACT in reducing the
incidence of malaria in various regions [16,17]. Since the
WHO memorandum in 2011, the use of artemisinin-
based monotherapies is no longer recommended [18].
The broad introduction of ACT in many African
countries offers the chance of monitoring drug-resistance development right from the start. Several
studies from neighbouring countries and from Ethiopia
showed high cure rates for AL and other ACT [19-26].
However, one recent study raised concerns over pro-
longed clearance rates in Africa [27].
The underlying study was aimed at investigating the
clinical and parasitological effectiveness of AL in Jimma
Zone two to three years after its broad introduction.
Methods
Study area and recruitment
Jimma is the capital of Jimma Zone in Oromiya regional
state and is located 355 km south-west of the Ethiopian
capital, Addis Ababa. Jimma Zone and its surroundings
are malaria endemic with a low to moderate transmission.
The predominant species in most areas is P. falciparum,
followed by P. vivax. Most cases occur from September to
December after the main rainy season from June to Au-
gust. Recruitment took place over eight months between
November 2008 to January 2009 and August 2009 to De-
cember 2009. Study sites were Agaro Health Centre,
Jimma Health Centre, Serbo Health Centre, and Asendabo
Health Centre (average elevation of study areas between
1,667 m to 1,772 m above sea level).
Study design and patients
The study was an open-label, single-arm, non-supervised
trial with standard treatment artemether-lumefantrine in
a six-dose, weight-adapted regimen. The study was
implemented in routine diagnostic of the health centres.
Blood slides were performed from all patients with fever.
Only falciparum mono-infection was considered for the
study. After microscopic confirmation, patients were
informed about the study and screened for eligibility if
consent was given.
Inclusion criteria were age above one year, body weight
above 5 kg, uncomplicated P. falciparum malaria
(mono-infection with P. falciparum), parasite density
1,000–100,000/μL, axillary temperature ≥37.5°C or
recorded history of fever within preceding 24 hrs, ability
to tolerate oral therapy, informed consent by the patient
or the legal representative as well as residency in the
study area. Treatment of uncomplicated malaria is on an
outpatient basis, therefore, eligibility for the study was
limited to residency in walking distance to the health
posts or the ability to use public transportation (<2
hours of travel time) due to the follow-up schedule of
the study.
Exclusion criteria were any anti-malarial treatment
within the previous seven days (anti-malarials like
chloroquine, AL, SP, quinine and others as well as anti-
biotics with anti-malarial effects like doxycycline, clinda-
mycine), mixed plasmodial infection, danger signs
(inability to drink, repeated vomiting, recent history of
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severe malaria as defined by the WHO [28] or any other
known severe underlying disease (eg, cardiac, renal, hep-
atic diseases, severe malnutrition, known HIV infection).
Patients with history of allergy or intolerance against
study medications, during pregnancy or lactation were
also excluded.
Ethical considerations
Each patient (or parents/guardians) received oral and
written information about the study and signed an
informed consent form. Ethical approval was obtained
from the Ethical Board of Jimma University, the Ethi-
opian Federal Ministry of Science and Technology,
and from the Ethical Committee of the Faculty of
Medicine of the Ludwig-Maximilian-University (LMU)
in Germany.
Treatment
The standard oral regimen of CoartemW (Novartis Phar-
maceuticals Corporation, Suffern, New York, USA for
Novartis AG, 20 mg artemether/120 mg lumefantrine)
was used for treatment which is supplied free of charge
by the government at health centres and hospitals. The
government is the only legal distributor of AL in Ethi-
opia. In a drug quality control centre in Addis Ababa,
drug tests are performed on a regular basis to exclude
fake drugs.
AL was administered as follows: 20 mg of artemether
and 120 mg of lumefantrine (children 5–14 kg), 40 mg/
240 mg (children 15–24 kg), 60 mg/360 mg (children
25–34 kg), 80 mg/480 mg (adults and children ≥35 kg
bwt.), at hrs 0, 8, 24, 36, 48 and 60 (six doses). Patients
were instructed to take the doses with fatty food. Full
treatment was supplied on admission. The first dose
was administered at the health centres by medical staff
under supervision. Full re-dosing was performed, if
vomiting occurred within 30 mins after the first dose
given. If a patient was unable to tolerate the medication,
treatment was discontinued and the patient referred to
the hospital for intravenous (IV) treatment with quin-
ine. Therapy for early treatment failures would have fol-
lowed the respective local guidelines for second-line
therapy and consisted of IV quinine. Late treatment
failures were treated with AL.
Examinations and follow-up procedures
Upon initial examination, a rapid screening procedure
was established. Blood was generally taken by finger-
prick method. Blood slides were prepared at initial
presentation for all patients with fever or history of
fever within 24 hrs, during routine examination at all
study centres. Sampling and preparation of thin and
thick smears was performed at each study centre byphysicians and laboratory technicians, who had been
trained and instructed by investigators at beginning of
the study. Microscopic assessment of Giemsa-stained
thin and thick blood smears confirmed P. falciparum
mono-infection.
A general physical examination was performed on ad-
mission. After recruitment, patients were questioned via
checklist about age, area of residency, underlying dis-
eases, symptoms, with special emphasis on danger signs
and symptoms for severe malaria and medications in the
previous three weeks. If included, the treatment was
given under observation and an additional blood sample
was spotted on filter paper (Whatman 3MM) (day 0).
Patients returned for outpatient follow-up on day 2, 3,
7, 28 and 42 (+/−7) and on any day before day 42 if any
symptoms recurred. Day 1 was not a regular study day
although patients were instructed to return immediately
if symptoms worsened. Each patient was asked on every
visit about past (since last visit) and present symptoms,
every adverse event was documented in specific case re-
port forms and later transferred to the database. Severe
adverse events had to be reported within 24 hours to the
study PI and the ethical boards. During follow-up, thin
and thick blood smears and blood-spotted filter papers
were simultaneously prepared on every visit for further
molecular investigations.
Endpoints
Primary and secondary endpoints were PCR-corrected
and uncorrected cure rates on days 28 and 42. Further
endpoints were treatment failures, completion of the
follow-up period without treatment failure meaning ad-
equate clinical and parasitological response (ACPR), loss
to follow-up, voluntary and involuntary withdrawal from
study and protocol violation. Treatment failures were
categorized as early treatment failure (ETF), late clinical
failure (LCF), and late parasitological failure (LPF)
according to the definition of treatment failures for low
to moderate transmission areas determined in the WHO
protocol issued in 2006. Other secondary endpoints
were defined as gametocytaemia at day 7 and day 28,
parasitaemia at day 2 and day 3, and PCR-corrected re-
infection rates at day 28 and day 42.
In vivo resistance definition and clearance time
calculation
Prolonged parasite presence (parasitaemia at day 3 ≥72
hours after treatment start) in ≥10% of cases after treat-
ment with an ACT is defined as suspected resistance
according to WHO [10], although this statement seems
to need further evaluation. Artemisinin resistance seems
to be highly unlikely if ≤3% patients show parasitaemia
at day 3, if initial parasite density was between 10,000-
100,000/μL [29].
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the formula of half-life time: e- λt.
λ= ln(0.5), constant of decay. P2 = parasitaemia at day
2, P0 = parasitaemia at day 0.
P2 = P0 (e
(−ln(0.5)/-t2)(48)) Correlating with t2 = (ln(0.5)/ln
(P0/P2)) (−48 hrs), for calculation of half-life time t2 be-
tween day 0 and day 2, meaning the time half the para-
sites were cleared every t2 during 48 hrs. Analogue
parasitaemia at day 3 and t3.
Laboratory examinations
Thin and thick blood smears were prepared according to
standard procedures. Slides were stained with 10%
Giemsa for 20 mins and independently read by two
microscopists. Parasite density was counted based on
standard procedures. The number of asexual parasites
was counted against 200 leukocytes assuming 8,000 leu-
kocytes per μL. Smears were determined to be negative
only after examining 120 fields [100x ocular]. Parasite
densities differing by more than 10% between microsco-
pists were controlled by a third microscopist, whose re-
sult was final.
DNA from dried blood spots on Whatman filter paper
(3MM) was extracted by Chelex method as described
elsewhere [30]. DNA from all samples from day 0, day
42 and from all treatment failures (recurrent parasit-
aemia) was extracted.
Molecular genotyping was performed by polymerase
chain reaction (PCR) from all samples from day 0 and
all treatment failures. Therefore, sequences of parasite
genes coding for the polymorphic proteins glutamate-
rich protein (GLURP) and merozoite surface proteins 1
and 2 (MSP-1 and MSP-2) were amplified by nested
PCR assays. Plasmodium falciparum isolates were
obtained at day 0 and any day of possible treatment fail-
ure up to day 42 of follow-up. PCR products of the
paired samples were compared. If any pre-treatment
alleles differed from post-treatment alleles, a new infec-
tion was considered; if no new allele in pre- and post-
treatment samples occurred, a recrudescence was
assumed [31,32].
Species amplification was performed by conventional
nested PCR described by Snounou [33]. The species
from all samples from day 0, day 42 and from all treat-
ment failures was determined.
For detection of mature gametocytes, the amplification
of Pfs25 mRNA by real-time quantitative nucleic acid se-
quence based amplification (QT-NASBA) was chosen as
target sequence as described elsewhere [34,35]. RNA ex-
traction was performed with using NucliSensW- easy-
MAGW Lysis Buffer. Filter paper was cut out and rocked
at 150 rpm for 30 mins at room temperature, following
the original RNA extraction method described by Boom
and colleagues [36]. The solution was centrifuged at1,500 g for 5 mins, the filter paper removed and 50 μl of
silica solution was added to the solution. The extraction
was made with the NucliSensW- mimiMAG ™ unit (bio-
Mérieux SA, Lyon, France) according to the manufac-
turer’s manual. Amplification was performed using
NucliSENS EasyQW Basic Kit (bioMérieux Bv, RM Boxtel,
The Netherlands) according to the manufacturer’s
manual and as described recently [35]. Microscopically
gametocyte-positive and a random selection of 10% of
microscopically gametocyte-negative samples were chosen.
Filter paper samples were stored at room temperature
until transport to Germany (one to 12 months) and then
stored at −20°C. DNA extraction was performed after ar-
rival of the samples in Germany. RNA extraction for
QT-NASBA was conducted about 18 months later.
Data management and statistical analysis
Data forms were checked regularly by the primary study
coordinator at the site. Double data entry in Excel
(Microsoft Office 2007) was independently performed in
Ethiopia and Germany. All data are subject to the data
protection and were processed anonymously. Data were
transferred to STATA, version 11, (Statacorp, 2009) and
analysis was performed. The traditional “per-protocol”
and “intention-to-treat” approach were applied. Logistic
regression models were used for a multivariate analysis
of outcome variables (primary and secondary endpoints)
and independent variables (age, gender, site, season,
weight, height). Comparison between two groups was
calculated by the Student’s t-test or Wilcoxon rank sum
test for continuous variables and the χ2 test or Fisher’s
exact test for categorical variables. Results were consid-
ered significant if p-values were <0.05.
The anticipated population proportion of clinical and
parasitological failures was estimated based upon the
data of a study at Jimma Hospital in 2006 [37]. The fail-
ure rate in a 42-day course was 0%; one symptomatic
parasitaemia occurred on day 70 that seemed to be a
recrudescence. Compared with other studies showing
failure rates of about 5%, a failure rate of maximum
10% was chosen [10]. Assuming follow-up losses and
withdrawals during a follow-up period longer than
14 days of 20% and ACPR of 90%, a sample size of
n = 400 was chosen to result in a confidence interval
from 86.71-93.29% on a 95% confidence level. Due to




The study was implemented in routine diagnostic of the
outpatient service (Figure 1). From 20,459 patients with
fever, thin and thick smears were taken for malaria diag-
nosis (official numbers from the health centres for the
Figure 1 Flowchart.
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malaria among these were 2,847 P. falciparum mono-
infections. Treatment of uncomplicated malaria is on
an outpatient basis. Eligibility for the study was limited
to residency near to the health posts due to the
follow-up schedule of the study. A total of 405 patients
with uncomplicated P. falciparum malaria were finally
enrolled from four different sites in Jimma Zone be-
tween November 2008 and January 2009 and from Au-
gust to December 2009. The study was planned to be
completed during the first sampling period 2008/2009
but sample collection had to be extended until end of
2009 due to weather conditions and logistics. Only
23% were recruited during the first season. Reasons for
non-eligibility were age below one year, underlying
chronic diseases, refusal, pregnancy, off-limits parasit-
aemia and in over 90% residency too far away from
the health centres.
Sixty percent of the patients were from Asendabo, 22%
from Jimma, 13% from Agaro and 5% from Serbo(Table 1); 60% were male; mean age was 17 years (95%
CI 15.7-18.5, range 1–81). Half of the patients were
under 16 years old, only 13% over 50. Children between
one and five years were equally distributed between sites.
Mean parasitaemia was significantly higher in infants
and children under six years (P = 0.004). Two-thirds of
the patients had a parasitaemia between 5,000-40,000/
μL, only 5% over 70,000/μL. Gametocyte prevalence at
recruitment was similar in both age groups; mean game-
tocytaemia was significantly lower in patients under six
years (P = 0.036).
Fifty-seven patients were excluded from the final ana-
lysis because PCR results showed mixed infection with
P. vivax (51) or negative results (six). Re-evaluation of
the slides confirmed the molecular results in some cases
but sub-microscopic parasitaemia of P. vivax was
assumed in most mixed infections. Molecularly negative
samples showed parasitaemia less than 1,000/μL in mi-
croscopy. All cases with mixed infections showed ad-
equate clinical and parasitological response at day 42.
Table 1 Baseline characteristics of enrolled patients, all
patients (A) and stratified by age group (B, under five
years and over five years)
A
Baseline characteristics n=348 95% CI range
Mean age (years) 17.1 15.7-18.5 1-81
Female (%) 40.2 35.0-45.4 -




Gametocytes present (%) 9.5 6.4-12.6 -
GM gametocyte density 1,305 899-1,894 40-6,798
B <5 years >5 years
Baseline characteristics n=64 95% CI n = 284 95% CI
Mean age (years) 3.3 2.9-3.6 20.2 18.7-21.7
Female (%) 46.9 34.3-59.4 38.7 33.0-44.4
Mean temperature (°C) 38.2 38.0-38.5 38.0 37.9-38.1
Geometric mean parasite
density
12,046 9,029-16,0731 9,262 8,299-10,336
Gametocytes present (%) 9.4 2.0-16.7 9.5 6.1-13.0
GM gametocyte density 435 82-2,3202 1,666 1,250-2,221
1Student’s t-test, P = 0.004 for a difference in means between the two age
groups.
2Wilcoxon rank sum test, P = 0.036 for a difference in means between the two
age groups.
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to follow-up during the study (Figure 1). The age was
equally distributed among those lost to follow-up and
all other study participants. The relation between chil-
dren ≤5 years and elder patients was similar in bothTable 2 Outcome at day 28 and 42 for all patients
Treatment outcome
Lost to follow-up (%)
Inability to tolerate oral treatment1 (%)
Early treatment failure (%)
Late treatment failure (%)
Late clinical failure (%)
Late parasitological failure
ACPR
Infection with different species (%)
New infection P. falciparum (%)
Recrudescences (%)
Cure rate per protocol, PCR-uncorrected (%, 95% CI)
Cure rate per protocol, PCR-corrected (%, 95% CI)
Cure rate intention-to-treat, PCR-uncorrected (%, 95% CI)
Cure rate intention-to-treat, PCR-corrected (%, 95% CI)
1 Those patients defined as “adverse event requiring change in anti-malarial therap
intention-to-treat analysis but excluded from the per-protocol analysis.groups but relatively more boys ≤5 years (73.5%) were
lost. There was no evidence for a real difference in
parasitaemia between those lost to follow-up and the
other participants (p>0.05). Those lost to follow-up
after day 2 were already negative in blood slides at
day 2.Study outcome
Until day 42, 286 patients showed an adequate clinical
and parasitological response (ACPR). Twenty-eight LTF
were observed during follow-up, 16 (4.6%) were LCF
and 12 (3.4%) were LPF. PCR-correction showed 16
recrudescences, of which 62.5% were symptomatic, and
incidence of 12 new infections. Recrudescences started
on day 18 until 42 (mean: 37 days); the first new infec-
tion occurred at day 28 (mean: 39 days).
The LTF rate was barely influenced by drop outs as
only one was lost to follow-up between day 28 and 42.
For per protocol (PP) analysis, PCR-corrected cure
rates at day 28 and 42 were 99.4 (95% CI 98.5-100.0)
and 94.7 (95% CI 92.2-97.2), respectively. Uncorrected
cure rates at day 28 and 42 were 99.1 (95% CI 98.0-
100.0) and 91.1 (95% CI 87.9-94.3), respectively (Table 2).
At day 42, PCR-corrected cure rate for children ≤5 years
was 90.6 (95% CI 82.4-98.7) compared to 95.6 (95% CI
93.0-98.2) in older patients, but the difference lacked
significance (P = 0.17) (Additional file 1).
For the intention to treat analysis (ITT), uncorrected
cure rates at day 28 and 42 were 89.7 (95% CI 86.4-92.9)
and 82.2 (95% CI 78.1-86.2), respectively; PCR-corrected
cure rates at day 28 and 42 were 89.9 (95% CI 86.7-93.1)
and 85.1 (95% CI 81.3-88.9), respectively (Table 2).Day 28 Day 42
31/348 (8.9) 32/348 (9.2)
2/348 (0.6) 2/348 (0.6)
0 0
3/348 (0.9) 28/348 (8.0)
3/348 (0.9) 16/348 (4.6)
0 12/348 (3.4)
312/348 (89.7) 286/348 (82.2)
0 0
1/348 (0.3) 12/348 (3.4)
2/348 (0.6) 16/348 (4.6)
312/315 (99.1, 98.0-100.0) 286/314 (91.1, 87.9-94.3)
312/314 (99.4, 98.5-100.0) 286/302 (94.7, 92.2-97.2)
312/348 (89.7, 86.4-92.9) 286/348 (82.2, 78.1-86.2)
312/347 (89.9, 86.7-93.1) 286/336 (85.1, 81.3-88.9)
y prior to completion of full dose of study drug”. They were included in the
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Fever was more rapidly cleared in patients >5 years
(Table 3).
Parasite clearance and associated variables
Six patients (1.9%) showed a prolonged duration till
clearance with parasites still present at day 2 (four
patients) - mean half-life t2 of 9.9 hours [range 7.3-13.9]
- and at day 3 (two patients) - mean half-life t3 of 21.4
hours [range 11.9-30.9]. All parasites were cleared at
day 7. For those without parasitaemia at day 2 or later,
mean half-life of <2.9-4.8 hours can be assumed, con-
sidering 1,000-100,000 parasite/μL at admission. Values
are only an approximation (±8 hours) as it was not pos-
sible to take the blood exactly 48 or 72 hours later
(Table 3).
Mean age of late responders (>48 hrs) was 11 years
[range 1.3-22.0]. They were from all clusters; two were
≤5 years, underweight and stunted. Initial parasitaemia
at day 0 was below 10,000/μL (mean parasitaemia 7,058/
μL, range 3,800-8,800/μL) in all six patients. Criteria for
an early treatment failure, defined by WHO [28], were
not fulfilled. Parasitaemia at day 3 was 20% and 2% of
day 0, respectively. Both patients with parasites at day 3
showed ACPR at day 42.
However, there was evidence for a strong association
of prolonged parasite presence (>48 hrs) with recrudes-
cence (OR 9.5, 95% CI 1.6-57.5, P = 0.01), meaning a re-
crudescence was 9.5 times more likely when parasites
were cleared after day 2 (Additional file 2).
Parasite density, on the other hand, seemed to have no
influence on recrudescent infections. Recrudescences
presented with a geometric mean parasitaemia of 8,665/







Day 2 1/60 (1.7) 10/274 (3.7) 11/334 (3.3)
Day 3 0 3/269 (1.1) 3/329 (0.9)
Microscopically determined parasitaemia, n/N (%)
Day 2 2/60 (3.3) 4/274 (1.4) 6/334 (1.8)
Day3 0 2/270 (0.7) 2/329 (0.6)
Microscopically determined gametocytaemia, n/N (%)
Day 0 6/64 (9.4) 26/284 (9.5) 33/348 (9.5)
Day 2 5/60 (8.3) 12/274 (4.4) 17/334 (5.1)
Day 3 4/60 (6.7) 6/269 (1.9) 10/329 (3.0)
Day 7 1/57 (1.8) 6/265 (2.3) 7/322 (2.2)
Day 28 1/54 (1.9) 2/259 (0.8) 3/313 (1.0)
Day 42 (37) 1/53 (1.9) 1/258 (0.4) 2/301 (0.7)parasitaemia of 286 patients with ACPR was 9,431/μL
(95% CI 8,402-10,586/μL). There was no evidence of a
real difference between these groups (P = 0.80).
Microscopic gametocyte clearance and associated
variables
Gametocyte prevalence was 9.5% by microscopy. Eighty
percent reduction could be observed between day 0 and
day 7 (Additional file 3). Only two patients developed
microscopic gametocytaemia after treatment start
(Table 3). Three patients had gametocytes on day 28.
They were already positive on day 0 and below 13 years
(median 7 years).
The association of recrudescences (after day 28) with
gametocytaemia at day 28 was significant (OR 38.5, 95%
CI 3.1-485.4, P<0.01) (Additional file 2). There was also
evidence for a strong association of prolonged parasite
presence with gametocytaemia on day 7 and day 28 (OR
10.1, 95% CI 1.0-99.8; P = 0.05 and OR 20.4, 95% CI 1.4-
309.8; P<0.03, respectively). Controlled for site, gender,
age and parasite density, the prevalence of gametocytes
at any point in time between day 0 to day 42 was more
likely in season 1 than in season 2 (OR 0.47, 95% CI
0.22-1.01, P = 0.05).
Molecular and submicroscopic investigations
Species PCR was done for all samples on day 42 with 12
(4.2%) of the 286 patients with ACPR being positive for
P. falciparum, no parasites were microscopically found.
Therefore, sub-microscopic levels of either asexual or
sexual parasitaemia can be assumed.
In 32 randomly chosen microscopically negative sam-
ples from day 0, the gametocyte-specific Pfs25-mRNA
could still be detected in 22 (70%) of the samples by
QT-NASBA. That means that microscopy revealed less
than one of seven of the prevalence of gametocytes in
these 32 patients. As storage duration and conditions of
filter-paper samples as well as blood spot sizes were not
standardized, molecular quantification of gametocytes
was not possible.
Symptoms, adverse events and pregnancy
Most patients had fever, headache, shivering and nausea
at admission. Abdominal pain and diarrhoea were less
frequent (Additional file 4): 2.9% of the patients had ad-
verse events (AE) on day 2 and 3.3% on day 3 with ab-
dominal pain and diarrhoea being the most prevalent
(Additional file 5). Two infants with high parasitaemia
(>95,000/μL) were recruited but did not tolerate oral
treatment. After re-dosing and repeated vomiting, the
infants were referred to the ward for intravenous treat-
ment; one died the same day. Both patients were
reported as serious adverse events (SAE) but classified
as “adverse event requiring change in anti-malarial
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A rapid aggravation of symptoms during the enrolment
procedure was suspected, no signs of severe malaria
were noticed at admission. Both children received IV
quinine, as oral therapy was not tolerated.
No further SAE occurred and no pregnancy (exclusion
criteria) was reported.Discussion
Of all 348 patients, 91.3% responded clinically and para-
sitically adequately to the treatment until day 42. Ad-
verse events were expectedly mild to moderate with low
prevalence. Abdominal pain and diarrhoea were the
most frequent symptoms.
The PCR-corrected failure rate showed incidence rates
of 3.8% for new infections and 5.1% for recrudescences
at day 42. No early treatment failure occurred. Com-
pared to a trial in 2006, these data show a slight increase
in recurrent parasitaemia as none had been detected
until day 42 [37].
Other Ethiopian studies detected also high cure rates
but most had a follow-up period of 28 days only [19-
23]. In this study, the PCR-corrected cure rate per
protocol at day 28 was 99.4% (95% CI 98.5-100.0).
This result emphasizes the need for follow-up periods
of at least 42 days. Most recrudescences occurred after
day 28. The recrudescence rate in children ≤5 years
was surprisingly high with 9.4%. None of the children
with recrudescences had diarrhoea or vomiting at ad-
mission or during therapy. Apart from limitations dis-
cussed in the next paragraph, the weight-adapted drug
dose is non-linear but stepwise. Two of the five chil-
dren with LTF had calculated drug doses of less than
2 mg/kg and 12 mg/kg body weight, respectively. Fur-
thermore, weight-adapted linear or non-linear doses
might not correlate with plasma drug levels in children
in general.
Unfortunately, there are several limitations concerning
this study. Drug levels were not tested and only the first
drug intake was observed. As absorption is fat-
dependent, fatty food was provided and patients were
precisely instructed how and when to take the rest of
the medication. However, intake was not directly con-
trolled and absorption individually varies, also impaired
by symptoms like diarrhoea [38]. Therefore, recrudes-
cences and also the prolonged parasite presence could
be due to insufficient drug levels. The advantage of this
study is the closer approach to a real life situation.
Another limitation is the method of genotyping. Dif-
ferentiation of recrudescences and re-infections by PCR
is unprecise, especially in low to moderate transmission
areas with a limited diversity of strains [32]. Similar
strains, defined as recrusdescence, could be newinfections instead. The recrudescence rate given might
be lower in reality.
Artemether has a very short half-life of about one
hour. Lumefantrine has a half-life of three to six days
and is able to clear the remaining parasites and to pre-
vent recurrent parasitaemia [39,40]. The first recrudes-
cence was observed early at day 18. However, due to
limitations mentioned above, other reasons than strain
resistance might have caused recrudescences. New
infections seemed to be efficiently prevented in the
first four weeks.
Six patients showed prolonged presence of parasites
detectable still at day 2 and day 3, the calculated half-life
time was prolonged. As stated above, this could have
been caused by low drug levels. Another theory is the
hypothesis of a dormant non-responding parasite stage
causing delayed susceptibility to drugs [41,42]. This
might be responsible for late clearance rates, though
genetic analysis revealed a heritable trait at the Cambo-
dia–Thailand border indicating changes in parasite gen-
etics and a potential for spread [15]. Controlled ACT
studies with measurement of drug levels and observed
drug intake should be conducted in Africa to examine
drug efficacy and clearance rates.
The low number of recrudescences and prolonged
parasite presence (>48 hrs) impaired multivariate ana-
lysis. Risk factors for these outcomes could not be
determined. There was strong evidence for an associ-
ation of both outcomes but the result has to be consid-
ered with caution as the sample size is low. However,
an association of recrudescence and prolonged parasite
presence (72 hrs) was described recently [29]. Parasite
clearance data from 18,699 patients with uncomplicated
falciparum malaria were analysed. Blood smear result
on day 3 was reported as a good predictor of subse-
quent treatment failure in low- and moderate-
transmission areas. The risk of recrudescence was <5%
if parasitaemia was cleared before day 3, patients with
parasitaemia on day 3 on the other hand had a signifi-
cantly higher risk in low-transmission areas (12%) and
in moderate-transmission areas (34%) to develop recru-
descences. Less pronounced but still significant was the
association of parasitaemia at day 2 and recrudescences
in moderate transmission areas.
This association was observed in the underlying study.
Recurrent parasitaemia occurred in two patients with
parasites at day 2 (P = 0.01). Prevalence of patients with
parasites at day 3 was 0.6% (2/348) only. Even if ad-
equate drug levels could be assumed, tolerance to arte-
mether would not be suspected. Artemisinin resistance
seems highly unlikely if prevalence of patients with para-
sites at day 3 is <3% [29].
Further analysis indicated a correlation of (prolonged)
presence of gametocytes with prolonged parasitaemia
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but associations seemed plausible. Gametocytes have
more opportunities to develop if parasite presence is
prolonged and sub-microscopic level as with recrudes-
cences seem to suffice for gametocyte production.
Interestingly, gametocytaemia was more frequent in
season 2008 than 2009. The broad introduction of
ACT in this region might have influenced the gameto-
cyte carriage in the population. ACT clears gameto-
cytes better than S/P, the previous first-line drug. ACT
is supposed to destroy the early stages of gametocytes
[16,43]. The carrier reservoir might be reduced since
introduction of ACT.
A random selection of samples showed very high
levels of gametocytaemia with QT-NASBA technique
compared to microscopy. Therefore, higher submicro-
scopic levels have to be assumed on recruitment as well
as after treatment. Recent studies showed a difference of
factor 3–6 between microscopic and submicroscopic
gametocyte prevalence [44,45]. Less than one gameto-
cyte per μL is sufficient to infect a mosquito [43]. Game-
tocytes detected by microscopy were rapidly reduced
under AL in this study but 2.2% of carriers remained
positive until day 7. A much higher proportion of sub-
microscopic gametocytaemia can be assumed. ACT
seems to have less or no effect on mature gametocytes
[16,43]. Therefore, stage V gametocytes, if already devel-
oped at start of therapy, might circulate for two to three
weeks. The reservoir is a permanent risk for further
transmission and should be measured in clinical trials as
well as in population-based studies with recently pub-
lished methods [35].
Further, an additional drug for gametocyte clearance
should be considered in the area. A single dose of
primaquine, best given at day 8, might be sufficient for
gametocyte clearance [46]. Unfortunately, prevalence of
G6PD enzyme deficiency is unknown. As tests are not
yet available in this area, the application of primaquine
remains ethically problematic, although single-dose
treatment seems acceptable [43].
Interestingly, P. falciparum mono-infection occurred
in only half of the malaria cases in the study area. Preva-
lence of mixed infections with P. vivax and infections
with P. vivax alone was high and has increased over the
last years [[9], pers comm with health centres in Jimma
and surrounding]. In Serbo, 70% of the malaria patients
were infected with P. vivax only. However, there was
surprisingly no re-infection with P. vivax observed. One
explanation for this and the very few re-infections with
P. falciparum might be that new bed nets were given
free of charge by the government to every patient visit-
ing the health centres.
Plasmodium vivax infections diagnosed by PCR and
afterwards excluded from analysis showed ACPR in allcases, no relapses occurred. Data on P. vivax and AL are
unavailable in this area. Chloroquine is still first-line
treatment of P. vivax. A recent study from another area
from Ethiopia observed treatment with AL and CQ in
vivax malaria. Recurrent parasitaemia rates were 19%
and 8%, respectively, although, the evening dose of AL
was not observed [47]. Studies from Asia reported
higher recurrence rates with AL compared to CQ or
dihydro-artemisinin/piperaquine as well [48,49]. How-
ever, relapses seem to occur in Ethiopia later than in
Asia [43] and might be expected after day 42.Conclusion
AL showed good effectiveness in Jimma. The overall
PCR-corrected cure rate per protocol was 94.7%, result-
ing in a recrudescence rate of below 10%. The PCR-
corrected per-protocol failure rate for children ≤5 years
was 9.4%. Low drug levels due to malabsorption and
dosing problems in children could be responsible. To
monitor closely the further development of drug sus-
ceptibility in this area, a continuous surveillance should
be established and controlled ACT studies with meas-
urement of drug levels and observed drug intake should
be conducted.
Additional files
Additional file 1: Outcome at day 42 stratified in age groups.
Description: The table shows the outcome at day 42 stratified in the age
groups> 5 years and≤ 5 years. The cure rates are in general lower for
the under five years old children but the difference is not significant.
Additional file 2: Association with outcome recrudescence (ACPR &
Recrudescences, n = 302). Description: The data show a multi-variate
analysis with the outcome recrudescences as dependent variable and
independent variables like parasitaemia at day 0, gametocytaemia over
time, and parasite clearance, controlled for age and gender. Delayed
clearance and gametocytaemie at day 28 were associated with
recrudescences. There was evidence for a strong association (P≤ 0.01)
but confidence intervals were wide.
Additional file 3: Clearance of microscopically detected
gametocytes over time. Description: Clearance of microscopically
detected gametocytes during follow-up in both age groups and overall.
Clearance in older patients seemed to be faster than in children below
6 years of age.
Additional file 4: Symptoms at recruitment (n = 348). Description:
The data show all symptoms presented at admission with absolute and
relative frequencies and duration. Fever, headache and shivering were
the leading symptoms.
Additional file 5: Adverse events (AE) during follow-up. Description:
The table presents all adverse events reported until day 7. Abdominal
pain was the most reported AE. Prevalence was overall low.
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